Press release
Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Nontuberculous Mycobacterial (NTM) Infections Pipeline
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Nontuberculous Mycobacterial (NTM) Infections pipeline constitutes 10+ key companies continuously working towards developing 10+ Nontuberculous Mycobacterial (NTM) Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Nontuberculous Mycobacterial (NTM) Infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial (NTM) Infections Market.
The Nontuberculous Mycobacterial (NTM) Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Nontuberculous Mycobacterial (NTM) Infections Pipeline Outlook [https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key takeaways from the Nontuberculous Mycobacterial (NTM) Infections Pipeline Report:
* Nontuberculous Mycobacterial (NTM) Infections Companies across the globe are diligently working toward developing novel Nontuberculous Mycobacterial (NTM) Infections treatment therapies with a considerable amount of success over the years.
* Nontuberculous Mycobacterial (NTM) Infections companies working in the treatment market are Mannkind Corporation, Paratek Pharmaceuticals, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others, are developing therapies for the Nontuberculous Mycobacterial (NTM) Infections treatment
* Emerging Nontuberculous Mycobacterial (NTM) Infections therapies such as MNKD-101, Omadacycline, CRS0393, MAT2501, and others are expected to have a significant impact on the Nontuberculous Mycobacterial (NTM) Infections market in the coming years.
* In April 2024, MannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease.
* In January 2024, Microbion Corporation announced that the company had been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.
* In September 2023, Insmed had reported positive results from the Phase III ARISE study of ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung disease, caused by Mycobacterium avium complex (MAC).
Nontuberculous Mycobacterial (NTM) Infections Overview
Nontuberculous Mycobacterial (NTM) infections are caused by a diverse group of mycobacteria that are commonly found in soil, water, and dust. Unlike Mycobacterium tuberculosis, NTM infections are not contagious and typically affect individuals with compromised immune systems or pre-existing lung conditions, such as chronic obstructive pulmonary disease (COPD) or cystic fibrosis. NTM infections can manifest in various forms, including pulmonary disease, lymphadenitis, skin and soft tissue infections, and disseminated disease.
The most prevalent species responsible for NTM pulmonary infections are Mycobacterium avium complex (MAC) and Mycobacterium abscessus. Symptoms of pulmonary NTM infections often resemble those of other respiratory conditions and may include chronic cough, fatigue, weight loss, and night sweats. Diagnosis typically involves a combination of clinical assessment, imaging studies, and microbiological tests, including culture and molecular techniques.
Treatment of NTM infections is challenging due to the intrinsic resistance of mycobacteria to many antibiotics. A typical treatment regimen includes a combination of multiple antibiotics over an extended period, often 12 months or more, based on the specific NTM species and the patient's response to therapy. Due to the prolonged and complex nature of treatment, patient management often requires a multidisciplinary approach involving pulmonologists, infectious disease specialists, and other healthcare professionals. Despite advances in diagnosis and treatment, NTM infections remain a significant clinical challenge, underscoring the need for ongoing research and development of more effective therapeutic strategies.
Get a Free Sample PDF Report to know more about Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutic Assessment- Nontuberculous Mycobacterial (NTM) Infections Treatment Market [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Nontuberculous Mycobacterial (NTM) Infections Route of Administration
Nontuberculous Mycobacterial (NTM) Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
Nontuberculous Mycobacterial (NTM) Infections Molecule Type
Nontuberculous Mycobacterial (NTM) Infections Products have been categorized under various Molecule types, such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutics Assessment
* Nontuberculous Mycobacterial (NTM) Infections Assessment by Product Type
* Nontuberculous Mycobacterial (NTM) Infections By Stage and Product Type
* Nontuberculous Mycobacterial (NTM) Infections Assessment by Route of Administration
* Nontuberculous Mycobacterial (NTM) Infections By Stage and Route of Administration
* Nontuberculous Mycobacterial (NTM) Infections Assessment by Molecule Type
* Nontuberculous Mycobacterial (NTM) Infections by Stage and Molecule Type
DelveInsight's Nontuberculous Mycobacterial (NTM) Infections Report covers around 4+ products under different phases of clinical development like-
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Nontuberculous Mycobacterial (NTM) Infections product details are provided in the report. Download the Nontuberculous Mycobacterial (NTM) Infections pipeline report to learn more about the emerging Nontuberculous Mycobacterial (NTM) Infections therapies- Nontuberculous Mycobacterial (NTM) Infections Drugs [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis:
The Nontuberculous Mycobacterial (NTM) Infections pipeline report provides insights into
* The Nontuberculous Mycobacterial (NTM) Infections pipeline report provides detailed insights about companies that are developing therapies for the treatment of Nontuberculous Mycobacterial (NTM) Infections with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nontuberculous Mycobacterial (NTM) Infections Treatment.
* Nontuberculous Mycobacterial (NTM) Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Nontuberculous Mycobacterial (NTM) Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nontuberculous Mycobacterial (NTM) Infections market.
Download Sample PDF Report to know more about Nontuberculous Mycobacterial (NTM) Infections drugs and therapies- Nontuberculous Mycobacterial (NTM) Infections Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of Nontuberculous Mycobacterial (NTM) Infections Pipeline Drug Insight
* Coverage: Global
* Key Nontuberculous Mycobacterial (NTM) Infections Companies: Mannkind Corporation, Paratek Pharmaceuticals, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others.
* Key Nontuberculous Mycobacterial (NTM) Infections Therapies: MNKD-101, Omadacycline, CRS0393, MAT2501, and others.
* Nontuberculous Mycobacterial (NTM) Infections Therapeutic Assessment: Nontuberculous Mycobacterial (NTM) Infections current marketed and Nontuberculous Mycobacterial (NTM) Infections emerging therapies
* Nontuberculous Mycobacterial (NTM) Infections Market Dynamics: Nontuberculous Mycobacterial (NTM) Infections market drivers and Nontuberculous Mycobacterial (NTM) Infections market barriers
Request for Sample PDF Report for Nontuberculous Mycobacterial (NTM) Infections Pipeline Assessment and clinical trials - Nontuberculous Mycobacterial (NTM) Infections Therapeutics Market [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Nontuberculous Mycobacterial (NTM) Infections Report Introduction
2. Nontuberculous Mycobacterial (NTM) Infections Executive Summary
3. Nontuberculous Mycobacterial (NTM) Infections Overview
4. Nontuberculous Mycobacterial (NTM) Infections- Analytical Perspective In-depth Commercial Assessment
5. Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutics
6. Nontuberculous Mycobacterial (NTM) Infections Late Stage Products (Phase II/III)
7. Nontuberculous Mycobacterial (NTM) Infections Mid Stage Products (Phase II)
8. Nontuberculous Mycobacterial (NTM) Infections Early Stage Products (Phase I)
9. Nontuberculous Mycobacterial (NTM) Infections Preclinical Stage Products
10. Nontuberculous Mycobacterial (NTM) Infections Therapeutics Assessment
11. Nontuberculous Mycobacterial (NTM) Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Nontuberculous Mycobacterial (NTM) Infections Companies
14. Nontuberculous Mycobacterial (NTM) Infections Key Products
15. Nontuberculous Mycobacterial (NTM) Infections Unmet Needs
16 . Nontuberculous Mycobacterial (NTM) Infections Market Drivers and Barriers
17. Nontuberculous Mycobacterial (NTM) Infections Future Perspectives and Conclusion
18. Nontuberculous Mycobacterial (NTM) Infections Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nontuberculous-mycobacterial-ntm-infections-pipeline-analysis-2024-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight here
News-ID: 3556552 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for NTM
Nontuberculous Mycobacterial Infection Market Outlook 2034 - Clinical Trials, Ma …
Nontuberculous Mycobacterial Infections Market Size in the US was approximately USD 360 million in 2023 and is projected to increase during the forecast period (2024-2034).
Nontuberculous Mycobacterial Market Summary
The Nontuberculous Mycobacterial (NTM) infections market is expected to grow steadily from 2024 to 2034, driven by improved diagnostics, new therapies, and greater disease awareness. Aging populations, who are more susceptible to NTM infections, contribute to rising diagnosed cases. Current treatments rely on…
Nontuberculous Mycobacterial (NTM) Infections Clinical Trials 2025: EMA, PDMA, F …
(Albany, United States) "Nontuberculous Mycobacterial (NTM) Infections Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial (NTM) Infections Market.
As per DelveInsight's assessment, globally, Nontuberculous Mycobacterial (NTM) Infections pipeline constitutes 10+ key companies continuously working towards developing 10+ Nontuberculous Mycobacterial (NTM) Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes…
Nontuberculous Mycobacterial Infections Treatment Market Size in the US was ~USD …
DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.
Discover Key Insights into the Nontuberculous Mycobacterial Market with DelveInsight's In-Depth Report @ Nontuberculous Mycobacterial Market Size [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Nontuberculous Mycobacterial Market Report
* In December 2024:- Parateek Pharmaceuticals- The purpose of this…
Nontuberculous Mycobacterium Treatment Market Forecasted to Achieve a CAGR of 7. …
Nontuberculous Mycobacterium Treatment Market Overview
The Nontuberculous Mycobacterium (NTM) Treatment Market was valued at USD 5.32 Bn in 2024. It is expected to reach USD 9.5 Bn by 2032, with a CAGR of 7.52% during the forecast period from 2025 to 2032.
The Nontuberculous Mycobacterium (NTM) Treatment Market is centered around the management and therapeutic options available for infections caused by nontuberculous mycobacteria, which are environmental organisms distinct from the mycobacteria responsible…
Hydrogen Concentration Sensors for Vehicle Market is Thriving Worldwide with Top …
Hydrogen Concentration Sensors for Vehicle Market Overview: Owing to a boom in the commercial industry, the demand for hydrogen sensors in automobiles is rising. Many certifying authorities employ sensors to assess the level of pollutants or the leaking in the cars. The need will increase as a result of technological developments and study expenditures for the creation of novel and inventive vehicle hydrogen sensor goods. The civilized world has a…
Global Waste or Garbage Collection Vehicle Market 2022 Development Factors - AUT …
The Global Waste or Garbage Collection Vehicle Market by MarketandResearch.biz assesses current market circumstances and forecasts industry growth for 2022-2028. This research examines current growth patterns, current growth factors, and future development projections in depth.
There are multiple sections to this. The market potential of each geographic location is assessed in terms of growth rate, macroeconomic indicators, and consumer purchasing habits in this study. Firms and other clients can utilise the…
